Dmitrii S. Demyanov
Dmitrii S. Demyanov has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander Alekseevich Pushkov
National Medical Research Center for Children’s Health, Ministry of Health of Russian Federation
4 shared publications - Kirill Victorovich Savostyanov
National Medical Research Center for Children’s Health, Moscow, Russia
4 shared publications - Iliya S. Zhanin
National Medical Research Center of Children’s Health, Ministry of Health of the Russian Federation, 119991 Moscow, Russia
3 shared publications - Anastasiya A. Lyalina
National Medical Research Center for Children’s Health
2 shared publications - Olga Borisovna Kondakova
National Medical Research Center for Children’s Health
2 shared publications - A. A. Chulkova
Kuzbass Children’s Clinical Hospital named after Professor Yu.E. Malakhovsky
1 shared publication
Latest Publications
- Open Access
- 5 July 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (2) , 126-132
Intrafamilial Polymorphism of Clinical Symptoms in Patients with Niemann-Pick Disease Type A
Introduction . Niemann-Pick disease type A (NPD type A) is the most severe form of acid sphingomyelinase deficiency, a rare inherited disorder of the lysosomal storage disorders with autosomal recessive inheritance caused by biallelic pathogenic variants in the SMPD1 gene. Since 2023, enzyme replacement therapy with olipudase alfa has been used to treat patients with NPD in Russia. This therapy does not alter the prognosis for neurological forms of the disease, as it does not penetrate the blood-brain barrier. Therefore, the only effective treatment, along with symptomatic therapy, for the systemic manifestations of NPD type A is hematopoietic stem cell transplantation, which does not prevent central nervous system damage. Early laboratory diagnostics using biochemical and molecular genetic diagnostic methods are crucial for timely diagnosis and treatment of patients with this form of the disease. Aim : to describe intrafamilial polymorphism of clinical symptoms of NPD, type A using the example of two siblings from the same family. Materials and methods . Clinical observation and diagnostics were conducted at the National Medical Research Center for Children’s Health of the Russian Ministry of Health from 2012 to 2026 in a single family in which the first proband with clinical symptoms characteristic of NBP type A was identified in 2012. Acid sphingomyelinase activity was measured in dried blood spots using tandem mass spectrometry, and nucleotide variants in the SMPD1 gene were identified using Sanger sequencing. Familial segregation analysis was performed for the proband and eight family members. Results . Diagnosis of the first proband revealed a significant decrease in acid sphingomyelinase activity in the patient’s spinal cord. Sequencing revealed the presence of two pathogenic heterozygous variants in the SMPD1 gene: c.996del ( p.Phe333Serfs52 ) and c.1252C > T ( p.Arg418 ). Carriage of the pathogenic causative variants in the SMPD1 gene was confirmed in the parents. The second proband was diagnosed on the second day of life. As a result of the timely diagnosis, immunotherapy (bone marrow transplant) was prescribed, which determined the child’s prognosis. Conclusion . Using two siblings from the same family as an example, polymorphism in the clinical symptoms of NPD type A was demonstrated. Early diagnosis of this form of the disease significantly improves the prognosis and enables timely initiation of therapy.
- 5 July 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (2) , 126-132
Open AccessIntrafamilial Polymorphism of Clinical Symptoms in Patients with Niemann-Pick Disease Type A
Introduction . Niemann-Pick disease type A (NPD type A) is the most severe form of acid sphingomyelinase deficiency, a rare inherited disorder of the lysosomal storage disorders with autosomal recessive inheritance caused by biallelic pathogenic variants in the SMPD1 gene. Since 2023, enzyme replacement therapy with olipudase alfa has been used to treat patients with NPD in Russia. This therapy does not alter the prognosis for neurological forms of the disease, as it does not penetrate the blood-brain barrier. Therefore, the only effective treatment, along with symptomatic therapy, for the systemic manifestations of NPD type A is hematopoietic stem cell transplantation, which does not prevent central nervous system damage. Early laboratory diagnostics using biochemical and molecular genetic diagnostic methods are crucial for timely diagnosis and treatment of patients with this form of the disease. Aim : to describe intrafamilial polymorphism of clinical symptoms of NPD, type A using the example of two siblings from the same family. Materials and methods . Clinical observation and diagnostics were conducted at the National Medical Research Center for Children’s Health of the Russian Ministry of Health from 2012 to 2026 in a single family in which the first proband with clinical symptoms characteristic of NBP type A was identified in 2012. Acid sphingomyelinase activity was measured in dried blood spots using tandem mass spectrometry, and nucleotide variants in the SMPD1 gene were identified using Sanger sequencing. Familial segregation analysis was performed for the proband and eight family members. Results . Diagnosis of the first proband revealed a significant decrease in acid sphingomyelinase activity in the patient’s spinal cord. Sequencing revealed the presence of two pathogenic heterozygous variants in the SMPD1 gene: c.996del ( p.Phe333Serfs52 ) and c.1252C > T ( p.Arg418 ). Carriage of the pathogenic causative variants in the SMPD1 gene was confirmed in the parents. The second proband was diagnosed on the second day of life. As a result of the timely diagnosis, immunotherapy (bone marrow transplant) was prescribed, which determined the child’s prognosis. Conclusion . Using two siblings from the same family as an example, polymorphism in the clinical symptoms of NPD type A was demonstrated. Early diagnosis of this form of the disease significantly improves the prognosis and enables timely initiation of therapy.
- Open Access
- 1 November 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (5) , 391-401
Success of Immunopathogenetic Therapy for Management of Congenital Ichthyosis, Combined Form, in a Child: Rare Clinical Case
Background. Congenital ichthyosis (CI) is relating to the group of clinical and genetically heterogeneous severe genodermatoses. SAM syndrome is included in classification of CI syndromic forms. Defects in the desmoplakin (DSP) and desmoglein 1 (DSG1) genes are the prime cause of disease. Impaired function of encoded proteins leads to desmosomal anomalies and disease symptoms. Comorbid atopic syndrome becomes the major cause of diagnostic mistakes. Patients are observed continuously with diagnosis “Atopic dermatitis (AD) torpid to standard treatment methods”. Clinical case description. This article describes a rare case of a boy with severe AD. Despite the chronic dermatosis several systemic disorders were revealed during examination: short stature, protein-energy malnutrition, adrenal insufficiency, juvenile polyarthritis, vitamin D deficiency, onychodystrophy, dysmorphic disorders. Molecular genetic study conducted via high-throughput sequencing followed by validation with Sanger sequencing has revealed two genetic variants: novel variant chr18:28934543G>T in the DSG1 gene in the heterozygous state and pathogenic variant chr5:157468728C>A in the NIPAL4 gene in the homozygous state. As a result, the final diagnosis was established: “SAM syndrome. Congenital ichthyosiform erythroderma”. Flow cytometry immunology study has shown dominant immunological profile of Th17-, and Thact-lymphocyte proliferation. The immunobiological therapy with IL-17A inhibitor, secukinumab, was initiated. Clinical efficacy was evaluated via ISS (Ichthyosis Severity Index), CDLQI (Children’s Dermatology Life Quality Index), pruritus numerical rating scale. ISS was 5.8 points, pruritus scale — 9, CDLQI — 24 at therapy initiation. Improvement in the skin condition was observed after a month of therapy. ISS was 1.2 points, pruritus scale — 2, CDLQI — 4 6 months after the therapy initiation. Conclusion. The diagnosis of a child with combined form of CI made it possible to change the management strategy, to prescribe pathogenetically justified targeted immunobiological therapy, and to achieve significant improvement in the child's health and quality of life, which does not differ from healthy peers.
- 1 November 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (5) , 391-401
Open AccessSuccess of Immunopathogenetic Therapy for Management of Congenital Ichthyosis, Combined Form, in a Child: Rare Clinical Case
Background. Congenital ichthyosis (CI) is relating to the group of clinical and genetically heterogeneous severe genodermatoses. SAM syndrome is included in classification of CI syndromic forms. Defects in the desmoplakin (DSP) and desmoglein 1 (DSG1) genes are the prime cause of disease. Impaired function of encoded proteins leads to desmosomal anomalies and disease symptoms. Comorbid atopic syndrome becomes the major cause of diagnostic mistakes. Patients are observed continuously with diagnosis “Atopic dermatitis (AD) torpid to standard treatment methods”. Clinical case description. This article describes a rare case of a boy with severe AD. Despite the chronic dermatosis several systemic disorders were revealed during examination: short stature, protein-energy malnutrition, adrenal insufficiency, juvenile polyarthritis, vitamin D deficiency, onychodystrophy, dysmorphic disorders. Molecular genetic study conducted via high-throughput sequencing followed by validation with Sanger sequencing has revealed two genetic variants: novel variant chr18:28934543G>T in the DSG1 gene in the heterozygous state and pathogenic variant chr5:157468728C>A in the NIPAL4 gene in the homozygous state. As a result, the final diagnosis was established: “SAM syndrome. Congenital ichthyosiform erythroderma”. Flow cytometry immunology study has shown dominant immunological profile of Th17-, and Thact-lymphocyte proliferation. The immunobiological therapy with IL-17A inhibitor, secukinumab, was initiated. Clinical efficacy was evaluated via ISS (Ichthyosis Severity Index), CDLQI (Children’s Dermatology Life Quality Index), pruritus numerical rating scale. ISS was 5.8 points, pruritus scale — 9, CDLQI — 24 at therapy initiation. Improvement in the skin condition was observed after a month of therapy. ISS was 1.2 points, pruritus scale — 2, CDLQI — 4 6 months after the therapy initiation. Conclusion. The diagnosis of a child with combined form of CI made it possible to change the management strategy, to prescribe pathogenetically justified targeted immunobiological therapy, and to achieve significant improvement in the child's health and quality of life, which does not differ from healthy peers.
- Open Access
- 31 July 2024
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 5 (2) , 66-78
Comorbid conditions in children with cystic fibrosis from various ethnic groups of the North Caucasus Federal District
Introduction. Cystic fibrosis (CF) is an autosomal recessive hereditary disease resulting from the presence of pathogenic nucleotide variants (NVs) in the CTFR gene, encoding a regulator of the transmembrane transport of chloride ions. CF is characterized by an impaired secretory function of the epithelial cells of exocrine glands and, as a consequence, a number of systemic progressive pathological changes in the functioning of the gastrointestinal tract, respiratory system, etc. CF might be accompanied by a number of comorbidities (CMs), including those leading to the development of mutual burden, affecting the diagnosis or choice of therapy. At the same time, of CMs repertoire in CF may vary in different ethnic groups and populations, especially geographically isolated ones. Thus, for more informed approach to the diagnosis and treatment of CF in certain ethnic groups and populations, it is necessary to determine the CMs repertoire characteristic of these groups. Materials and methods. The study included one hundred twenty five 2 months to 17 years and 11 months patients with a confirmed diagnosis of CF. The children were divided into groups according to ethnicity: residents of the Chechen Republic (71 patient), residents of the Karachay-Cherkess Republic (23 patients), residents of the Republic of Ingushetia (9 patients), the Republic of Dagestan (16 patients), the Republic of North Ossetia — Alania (6 patients). Results. The frequencies and spectrum of comorbidities (CMs) in CF children from ethnic groups living in the North Caucasus Federal District differ from those previously described for CF patients from other populations and ethnic groups. The most common CMs identified in this study are adenoid hypertrophy (n = 51; 40.8%), chronic gastritis (n = 47; 37.6%), lactase deficiency (n = 38; 30.4%), gastroesophageal reflux disease (n = 30; 24%), development retardation (n = 22; 17.6%), allergies of various origins (n = 21; 16.8%), and consequences of perinatal damage to the central nervous system (n = 11; 8.8%). Conclusion. For the early differential diagnosis of CMs and further clinical management of pediatric CF patients, it is necessary to implement an interdisciplinary approach using of medical genetic methods, as well as additional monitoring by several medical specialists. First and foremost, the decision on which medical specialists should be involved in a clinical management of such patients should be based on the CMs repertoire prevailing in a given population or ethnic group. When performing a clinical monitoring of the CF children from the ethnic groups living predominantly in the North Caucasus Federal District, it is advisable to choose the therapeutic approach that takes into account the ethnic-specific features of CMs, identified in our work.
- 31 July 2024
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 5 (2) , 66-78
Open AccessComorbid conditions in children with cystic fibrosis from various ethnic groups of the North Caucasus Federal District
Introduction. Cystic fibrosis (CF) is an autosomal recessive hereditary disease resulting from the presence of pathogenic nucleotide variants (NVs) in the CTFR gene, encoding a regulator of the transmembrane transport of chloride ions. CF is characterized by an impaired secretory function of the epithelial cells of exocrine glands and, as a consequence, a number of systemic progressive pathological changes in the functioning of the gastrointestinal tract, respiratory system, etc. CF might be accompanied by a number of comorbidities (CMs), including those leading to the development of mutual burden, affecting the diagnosis or choice of therapy. At the same time, of CMs repertoire in CF may vary in different ethnic groups and populations, especially geographically isolated ones. Thus, for more informed approach to the diagnosis and treatment of CF in certain ethnic groups and populations, it is necessary to determine the CMs repertoire characteristic of these groups. Materials and methods. The study included one hundred twenty five 2 months to 17 years and 11 months patients with a confirmed diagnosis of CF. The children were divided into groups according to ethnicity: residents of the Chechen Republic (71 patient), residents of the Karachay-Cherkess Republic (23 patients), residents of the Republic of Ingushetia (9 patients), the Republic of Dagestan (16 patients), the Republic of North Ossetia — Alania (6 patients). Results. The frequencies and spectrum of comorbidities (CMs) in CF children from ethnic groups living in the North Caucasus Federal District differ from those previously described for CF patients from other populations and ethnic groups. The most common CMs identified in this study are adenoid hypertrophy (n = 51; 40.8%), chronic gastritis (n = 47; 37.6%), lactase deficiency (n = 38; 30.4%), gastroesophageal reflux disease (n = 30; 24%), development retardation (n = 22; 17.6%), allergies of various origins (n = 21; 16.8%), and consequences of perinatal damage to the central nervous system (n = 11; 8.8%). Conclusion. For the early differential diagnosis of CMs and further clinical management of pediatric CF patients, it is necessary to implement an interdisciplinary approach using of medical genetic methods, as well as additional monitoring by several medical specialists. First and foremost, the decision on which medical specialists should be involved in a clinical management of such patients should be based on the CMs repertoire prevailing in a given population or ethnic group. When performing a clinical monitoring of the CF children from the ethnic groups living predominantly in the North Caucasus Federal District, it is advisable to choose the therapeutic approach that takes into account the ethnic-specific features of CMs, identified in our work.
- Open Access
- 24 May 2024
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 14 (2) , 78‑91
Delayed motor, mental and speech development and congenital brain malformations: the first description of Zhu–Tokita–Takenouchi–Kim syndrome in Russia
Zhu–Tokita–Takenouchi–Kim syndrome (ZTTK syndrome) is a rare autosomal dominant nuclear speckleopathy characterized by developmental delay, hypotonia, intellectual disability, facial dysmorphism in association with variable brain malformations, musculoskeletal abnormalities and ocular involvement. Currently, 87 cases of ZTTK syndrome have been described worldwide. The syndrome caused by mutations in the SON gene, located on the long arm of chromosome 21 (21q22.11). Nonsense and frameshift mutations have been described in the SON gene. Missense mutations, partial or whole gene deletions are less common.The aim of the work is to analyze the clinical picture and molecular genetic results of patients with confirmed ZTTK syndrome and compare them with data from foreign literature.We observed the one boy and two girls with ZTTK syndrome aged 13 months to 59 months, averaging about 38 months. DNA diagnostic was performed by next generation sequencing. All patients and all parents were confirmed by Sanger sequening. Three pathogenic variants were identified: c.5753_5756delTTAG (p.Val1918Glufs*87), c.1531del (p.Thr511Glnfs*9) and c.403delG (p.Glu135Asnfs*14). The first one was is most common, the other two are novel variants. Most patients had growth, motor and speech delay, seizures, hypotonia, congenital heart defects, urinary tract abnormalities and brain malformations. Comparative analysis of facial features in patients with ZTTK syndrome showed downslanting palpebral fissures, epicantal folds, broad or depressed nasal bridge, flared nares, smooth philtrum, thin upper lip and low set, rotated ears. The use of next generation sequencing as a first‑line test for research and diagnostic of ZTTK syndrome is advisable due to the pronounced clinical polymorphism.
- 24 May 2024
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 14 (2) , 78‑91
Open AccessDelayed motor, mental and speech development and congenital brain malformations: the first description of Zhu–Tokita–Takenouchi–Kim syndrome in Russia
Zhu–Tokita–Takenouchi–Kim syndrome (ZTTK syndrome) is a rare autosomal dominant nuclear speckleopathy characterized by developmental delay, hypotonia, intellectual disability, facial dysmorphism in association with variable brain malformations, musculoskeletal abnormalities and ocular involvement. Currently, 87 cases of ZTTK syndrome have been described worldwide. The syndrome caused by mutations in the SON gene, located on the long arm of chromosome 21 (21q22.11). Nonsense and frameshift mutations have been described in the SON gene. Missense mutations, partial or whole gene deletions are less common.The aim of the work is to analyze the clinical picture and molecular genetic results of patients with confirmed ZTTK syndrome and compare them with data from foreign literature.We observed the one boy and two girls with ZTTK syndrome aged 13 months to 59 months, averaging about 38 months. DNA diagnostic was performed by next generation sequencing. All patients and all parents were confirmed by Sanger sequening. Three pathogenic variants were identified: c.5753_5756delTTAG (p.Val1918Glufs*87), c.1531del (p.Thr511Glnfs*9) and c.403delG (p.Glu135Asnfs*14). The first one was is most common, the other two are novel variants. Most patients had growth, motor and speech delay, seizures, hypotonia, congenital heart defects, urinary tract abnormalities and brain malformations. Comparative analysis of facial features in patients with ZTTK syndrome showed downslanting palpebral fissures, epicantal folds, broad or depressed nasal bridge, flared nares, smooth philtrum, thin upper lip and low set, rotated ears. The use of next generation sequencing as a first‑line test for research and diagnostic of ZTTK syndrome is advisable due to the pronounced clinical polymorphism.
- 1 January 2024
- Published by Dynasty Publishing House in Voprosy praktičeskoj pediatrii
- Vol. 19 (5)
Features of clinical and laboratory manifestations of undifferentiated autoinflammatory diseases in patients – carriers of variants in genes associated with autoinflammation
Undifferentiated autoinflammatory diseases (uAIDs) constitute a group of rare autoinflammatory diseases that do not correspond in their phenotype and genotype to known monogenic AIDs. They often manifest as juvenile arthritis, particularly its systemic variant. A comprehensive understanding of the clinical, laboratory, and genetic characteristics of undifferentiated AIDs is essential for timely diagnosis and the initiation of targeted therapy. This approach can reduce the risk of complications, disability, and improve prognosis. Objective. To identify the peculiarities of clinical and laboratory manifestations of undifferentiated autoinflammatory diseases in patients – carriers of variants in genes associated with autoinflammation. Patients and methods. We performed a comparative retrospective analysis of clinical and laboratory manifestations of disease in 52 patients with febrile syndrome hospitalised in the rheumatology department of the National Medical Research Centre for Child Health between 1 March 2013 and 31 August 2022, with a referral diagnosis of juvenile idiopathic arthritis (JIA): 26 (50%) patients each with and without variants in genes associated with autoinflammation. Results. Due to the presence of febrile syndrome, molecular genetic study was performed in all patients. No variants in genes associated with known monogenic AID were detected in any patient. In 26 patients, 36 variants in genes associated with autoinflammation were identified, including: 1 (2.8%) variant classified as pathogenic in the TREX1 gene (c.914A>G, p.Y305C), 1 (2.8%) probably pathogenic variant in the NFAT5 gene (c.74-1 G>C), 4 (11.1%) were probably benign variants in STAT2, IL23R, TNFRSF1B and PSMB8 genes, 30 (83.3%) were variants of uncertain significance in IL10 genes, NLRP12, LPIN2, NLRC4, PSMB8, PRF1, CARD14, IFIH1, LYST, COPA, PLCG2, STXBP2, LACC1, PTHR1, STAT4, TNFAIP3, SLC7A7, all in heterozygous state. Patients with variants in genes associated with autoinflammation and a disease phenotype corresponding to uAID (n = 26) were verified as having uAID, while patients without variants in genes and a disease phenotype not corresponding to AID were confirmed as having systemic JIA (sJIA). At disease debut, fever was recorded in all patients, rash and joint involvement in 51 (98%) and 46 (88.5%) patients in the total cohort: of these, 26 (100%) and 25 (96.1%); 24 (92.3%) and 22 (84.7%) patients with uAIDs and sJIA, respectively. Similar symptoms in patients with uAIDs and sJIA were characterised by the following features: in sJIA, the fever was continuous and the rash was patchy-papular; in uAIDs, the fever lasted <7 days and the rash was predominantly erythematous, urticarial, small-spotted, large-spotted and mixed. Patients with uAIDs had clinical manifestations that were absent in patients diagnosed with sJIA: attack-like fever (100%), erythematous (15.3%), erythematous (15.3%), urticarial (11.5%), mixed rash (3.8%), eye lesions (conjunctivitis and congenital cataract) (11.5%), hydrocephalus (3.8%), combination of hydrocephalus and psycho-verbal retardation (3.8%), combination of headache and psycho-verbal retardation (3.8%), hearing loss (3.8%). Conclusion. The presence of variants in genes associated with autoinflammation can manifest a wide variety of clinical symptoms, therefore, it is advisable to perform molecular genetic studies to detect variants in genes in all patients with suspected sJIA, fever, joint involvement in combination with rash, eye inflammation, central nervous system involvement and/or other manifestations, associated with AID/autoinflammation to confirm/exclude the diagnosis of known monogenic or multifactorial AID at an early stage, timely verification of the diagnosis of uAID, initiation of pathogenetic therapy and prevention of complications. Key words: autoinflammatory syndrome, undifferentiated autoinflammatory diseases, undifferentiated recurrent fever syndrome, molecular genetic diagnosis, rheumatology, paediatrics, children
- 1 January 2024
- Published by Dynasty Publishing House in Voprosy praktičeskoj pediatrii
- Vol. 19 (5)
Features of clinical and laboratory manifestations of undifferentiated autoinflammatory diseases in patients – carriers of variants in genes associated with autoinflammation
Undifferentiated autoinflammatory diseases (uAIDs) constitute a group of rare autoinflammatory diseases that do not correspond in their phenotype and genotype to known monogenic AIDs. They often manifest as juvenile arthritis, particularly its systemic variant. A comprehensive understanding of the clinical, laboratory, and genetic characteristics of undifferentiated AIDs is essential for timely diagnosis and the initiation of targeted therapy. This approach can reduce the risk of complications, disability, and improve prognosis. Objective. To identify the peculiarities of clinical and laboratory manifestations of undifferentiated autoinflammatory diseases in patients – carriers of variants in genes associated with autoinflammation. Patients and methods. We performed a comparative retrospective analysis of clinical and laboratory manifestations of disease in 52 patients with febrile syndrome hospitalised in the rheumatology department of the National Medical Research Centre for Child Health between 1 March 2013 and 31 August 2022, with a referral diagnosis of juvenile idiopathic arthritis (JIA): 26 (50%) patients each with and without variants in genes associated with autoinflammation. Results. Due to the presence of febrile syndrome, molecular genetic study was performed in all patients. No variants in genes associated with known monogenic AID were detected in any patient. In 26 patients, 36 variants in genes associated with autoinflammation were identified, including: 1 (2.8%) variant classified as pathogenic in the TREX1 gene (c.914A>G, p.Y305C), 1 (2.8%) probably pathogenic variant in the NFAT5 gene (c.74-1 G>C), 4 (11.1%) were probably benign variants in STAT2, IL23R, TNFRSF1B and PSMB8 genes, 30 (83.3%) were variants of uncertain significance in IL10 genes, NLRP12, LPIN2, NLRC4, PSMB8, PRF1, CARD14, IFIH1, LYST, COPA, PLCG2, STXBP2, LACC1, PTHR1, STAT4, TNFAIP3, SLC7A7, all in heterozygous state. Patients with variants in genes associated with autoinflammation and a disease phenotype corresponding to uAID (n = 26) were verified as having uAID, while patients without variants in genes and a disease phenotype not corresponding to AID were confirmed as having systemic JIA (sJIA). At disease debut, fever was recorded in all patients, rash and joint involvement in 51 (98%) and 46 (88.5%) patients in the total cohort: of these, 26 (100%) and 25 (96.1%); 24 (92.3%) and 22 (84.7%) patients with uAIDs and sJIA, respectively. Similar symptoms in patients with uAIDs and sJIA were characterised by the following features: in sJIA, the fever was continuous and the rash was patchy-papular; in uAIDs, the fever lasted <7 days and the rash was predominantly erythematous, urticarial, small-spotted, large-spotted and mixed. Patients with uAIDs had clinical manifestations that were absent in patients diagnosed with sJIA: attack-like fever (100%), erythematous (15.3%), erythematous (15.3%), urticarial (11.5%), mixed rash (3.8%), eye lesions (conjunctivitis and congenital cataract) (11.5%), hydrocephalus (3.8%), combination of hydrocephalus and psycho-verbal retardation (3.8%), combination of headache and psycho-verbal retardation (3.8%), hearing loss (3.8%). Conclusion. The presence of variants in genes associated with autoinflammation can manifest a wide variety of clinical symptoms, therefore, it is advisable to perform molecular genetic studies to detect variants in genes in all patients with suspected sJIA, fever, joint involvement in combination with rash, eye inflammation, central nervous system involvement and/or other manifestations, associated with AID/autoinflammation to confirm/exclude the diagnosis of known monogenic or multifactorial AID at an early stage, timely verification of the diagnosis of uAID, initiation of pathogenetic therapy and prevention of complications. Key words: autoinflammatory syndrome, undifferentiated autoinflammatory diseases, undifferentiated recurrent fever syndrome, molecular genetic diagnosis, rheumatology, paediatrics, children